|
Originally published In Press as doi:10.1074/jbc.M102441200 on May 30, 2001
J. Biol. Chem., Vol. 276, Issue 33, 31247-31256, August 17, 2001
Initiation of HIV-1 Reverse Transcription Is
Regulated by a Primer Activation Signal*
Nancy
Beerens,
Fedde
Groot, and
Ben
Berkhout
From the Department of Human Retrovirology, Academic Medical
Center, University of Amsterdam,
1100 DE Amsterdam, The Netherlands
Received for publication, March 19, 2001, and in revised form, May 8, 2001
 |
ABSTRACT |
Reverse transcription of the human
immunodeficiency virus type 1 (HIV-1) RNA genome appears to be strictly
regulated at the level of initiation. The primer binding site (PBS), at
which the tRNA molecule
anneals and reverse transcription is initiated, is present in a highly
structured region of the untranslated leader RNA. Detailed mutational
analysis of the U5 leader stem identified a sequence motif in the U5
region that is critical for activation of the PBS-bound
tRNA primer. This U5 motif, termed the primer
activation signal (PAS), may interact with the T C arm of the
tRNA primer, similar to the additional interaction
proposed for the genome of Rous sarcoma virus and its
tRNATrp primer. This suggests that reverse transcription is
regulated by a common mechanism in all retroviruses. In HIV-1, the PAS
is masked through base pairing in the U5 leader stem. This provides a
mechanism for positive and negative regulation of reverse
transcription. Based on structure probing of the mutant and wild-type
RNAs, an RNA secondary structure model is proposed that juxtaposes the critical PAS and PBS motifs.
 |
INTRODUCTION |
Infection of the host cell by a retroviral particle results in
reverse transcription of the viral RNA genome into double-stranded DNA,
which subsequently becomes integrated into the host cell genome (1).
Reverse transcription is mediated by the virion-associated enzyme
reverse transcriptase (RT),1
and a cellular tRNA molecule is used as a primer (2). The tRNA primer
binds with its 3'-terminal 18 nts to a complementary sequence, the
primer binding site (PBS), that is located in the 5'-untranslated
leader region of the viral RNA genome. Retroviral particles are
competent to initiate reverse transcription shortly after budding from
the producer cell, but there is also evidence that reverse
transcription in virions is limited (3-7). This suggests that
initiation of reverse transcription is restricted until a new host cell
is infected. The mechanism that regulates reverse transcription is not
known, but sequence motifs and RNA secondary structures in the region
flanking the PBS have been implicated (8-13). Alternatively, reverse
transcription may be restricted in extracellular virions by the low
concentration of dNTP molecules in virus particles.
In the genome of human immunodeficiency virus type I (HIV-1), the PBS
is predicted to be part of an extended RNA structure. Several RNA
secondary structure models have been proposed for this region of the
5'-untranslated leader (14-17), and there is recent evidence that this
region can adopt alternate conformations (18, 19). The model depicted
in Fig. 1A shows the U5-PBS hairpin that occludes part of
the PBS and the extended U5 leader stem, which is formed by base
pairing of sequences in the upstream U5 and the downstream leader
region. Similar RNA secondary structures have been predicted for other
retroviruses (16, 20-23). For the avian Rous sarcoma virus (RSV),
these structures have been reported to regulate initiation of reverse
transcription (8-10, 24). In RSV, reverse transcription is stimulated
by an additional vRNA-tRNA interaction between a sequence motif in the
U5 region and the T C arm of the tRNATrp primer (22). For
HIV-1 reverse transcription, initiation is thought to be stimulated by
other template-primer contacts, including a base-pairing interaction
between the A-rich loop of the U5-PBS hairpin and the anti-codon loop
of the tRNA primer (12, 13,
25-30).
In this study, we present a detailed mutational analysis of the HIV-1
U5 leader stem. We measured the replication capacity of the mutant
viruses and performed in vitro reverse transcription assays
with the mutant RNA templates. Analysis of HIV-1 mutants with large
deletions suggested that the U5 region contains a motif that is
critical for tRNA -mediated
initiation of reverse transcription but not for reactions that are
initiated by a DNA primer. A second set of mutants was designed to map
this HIV-1 RNA motif in more detail. We identified an eight-nucleotide sequence in the U5 region that is not involved in tRNA annealing but
that is important for initiation of reverse transcription. We propose
that this motif interacts with the T C arm of
tRNA , thereby triggering initiation
of HIV-1 reverse transcription. This U5 motif, termed primer activation
signal (PAS), is masked in the wild-type RNA through base pairing in
the U5 leader stem. Interestingly, reverse transcription can be
activated by exposure of the PAS through mutation of the "opposing"
leader sequence. The presence of the PAS enhancer element and a
repressive RNA structure provides a mechanism for positive and negative
regulation of reverse transcription. In addition, we performed
structure probing of the mutant and wild-type RNAs to resolve the
secondary structure of the PBS domain. An RNA secondary structure model is proposed in which the PAS and PBS motifs are juxtaposed. Overall, regulation of reverse transcription in HIV-1 appears to be very similar
to that in RSV, suggesting that reverse transcription is regulated by a
common mechanism in all retroviruses.
 |
EXPERIMENTAL PROCEDURES |
DNA Constructs--
A derivate of the full-length
proviral HIV-1 clone pLAI was used to produce wild-type and U5 leader
stem-mutated viruses. This construct pLAI-R37 has been described
previously and contains a unique U5 region in the 5'-LTR (31).
Nucleotide numbers refer to positions on HIV-1 genomic RNA, with +1
being the capped G residue. For mutation of the U5 leader stem, we used
the construct Blue-5'-LTR (32), which contains a
XbaI-ClaI fragment of HIV-1, encompassing the
5'-LTR, PBS, leader, and the 5' end of the gag gene
(positions 454 to +376) cloned into pBluescript KS+ (Stratagene). The
U5 leader stem was mutated by oligonucleotide-directed in vitro mutagenesis with a Muta-Gene Phagemid in Vitro
mutagenesis kit (Bio-Rad). For sequence analysis, the 5'-LTR leader
region was PCR-amplified with the sense R region primer T7-1 (positions 54 to 34) with the 5'-flanking T7 RNA polymerase promoter sequence and the antisense primer AUG (positions +348 to +368, with 6 additional nucleotides at its 5'-end). These PCR products were sequenced with the
DYEnamicTM Direct cycle sequencing kit (Amersham Pharmacia
Biotech) and an Applied Biosystems 373 DNA sequencer. Subsequently, the
mutated XbaI-ClaI fragments were introduced into
the proviral clone pLAI-R37, which was checked by sequence analysis of
the mutated domain.
Cells, Transfection, and Virus Replication--
SupT1 T cells
were grown in RPMI 1640 medium supplemented with 10% fetal calf serum
at 37 °C and 5% CO2. SupT1 cells (5 × 106) were transfected with 1 µg of the HIV-1 proviral
constructs by electroporation (250 V, 960 microfarads). Fresh SupT1
cells (0.5 × 106) were added after transfection to
support virus replication. Cells were split 1 to 10 twice a week.
CA-p24 levels in the culture medium were determined by enzyme-linked
immunosorbent assay (33).
Synthesis of RNA Templates--
The wild-type and mutant
pBlue-5'-LTR plasmids were used as the template for PCR amplification
and subsequent in vitro transcription. The 5'-LTR-leader
region was PCR-amplified with the sense primer T7-2 (positions +1 to
+20) with 5'-flanking T7 RNA polymerase promoter sequence and the
antisense primer AUG (positions +348 to +368). The PCR fragments were
phenol-extracted, precipitated and dissolved in water. In
vitro transcription was performed with the T7-MegaShortscript kit
(Ambion). Upon DNase treatment and phenol extraction, the
unincorporated free nucleotides were removed by passage through a
Sephadex G-50 column. Subsequently, the RNA was ethanol-precipitated
and dissolved in renaturation buffer (10 mM Tris-HCl, pH
7.5, 100 mM NaCl). The RNA was renatured by incubation at
85 °C for 2 min followed by slow cooling to room temperature, and
the RNA was stored at 20 °C. The RNA concentration was measured by
UV spectroscopy.
Reverse Transcription Assays--
The in vitro
synthesized RNA template (10 ng) was incubated either with 1.5 µg of
calf liver tRNA (6 pmol total tRNA, of which ~1.2 pmol
tRNA , Roche Molecular Biochemicals) or with 20 ng of DNA primer in 12 µl of annealing buffer (83 mM Tris-HCl, pH 7.5, 125 mM KCl) at 85 °C
for 2 min, 65 °C for 10 min, followed by cooling to room temperature
over a 1-h period. We previously demonstrated that there is selective
priming by tRNA in this system (6).
Even the related tRNALys1,2 molecules do not act as a
primer. The primer was extended with 1 nt by the addition of 6 µl of
RT( ) buffer (9 mM MgCl2, 30 mM dithiothreitol, 150 µg/ml actinomycin D), 1 µl of
[ -32P]dCTP, and 0.5 units of HIV-1 RT (Medical
Research Council AIDS Reagent Project). Reverse transcription was
performed for 30 min at 37 °C. Complete cDNA synthesis was
accomplished in RT(+) buffer (RT( ) buffer with 30 µM
dATP, dGTP, and dTTP and 1.5 µM dCTP), 0.3 µl of
[ -32P]dCTP, and 0.5 units of HIV-1 RT. In the PBS
occupancy assay, the RNA template was incubated simultaneously with 1.5 µg of calf liver tRNA and 20 ng of AUG primer, and reverse
transcription was performed in RT(+) buffer with avian myeloblastosis
virus RT enzyme (Roche Molecular Biochemicals). The cDNA products
were precipitated in 0.3 M sodium acetate, pH 5.2, and 70%
ethanol at 20 °C, dissolved in formamide-loading buffer, heated,
and analyzed on a denaturing 6% polyacrylamide-urea-sequencing gel. The antisense primers used are poly(A) (positions +77 to +104), Lys-21
(positions +182 to +202), and AUG (positions +348 to +368, with 6 additional nucleotides at its 5' end). Sequence reactions with the BB-3
(positions +215 to +245) and AUG primer were performed with the
Sequenase kit 2.0 (Amersham Pharmacia Biotech) and included on the
sequencing gels to determine the exact length of the cDNA products.
Structure Probing of U5 Leader Stem--
In vitro
synthesized HIV-1 leader RNA (positions +1 to +368) (50 ng) was treated
with diethyl pyrocarbonate (DEPC, 0.5%/2.5%), dimethyl sulfate (DMS,
0.1/0.5%), RNase T1 (0.004 units/0.02 units), RNase S1 (2 units/10
units), or RNase One (10 5 units/5 × 10 5 units) in 10 mM Tris, pH 8.5, 10 mM MgCl2, 50 mM NaCl for 10 min at
37 °C. The samples treated were phenol-extracted and recovered by
ethanol precipitation. The antisense primers AD-SD (positions + 270 to
+290) and Lys-21 (positions +182 to +202) were used to map the sites of
modification or cleavage. Primers were end-labeled with
[ -32P]ATP and T4 polynucleotide kinase (Roche
Molecular Biochemicals). The labeled oligonucleotide (2 ng) was mixed
with the RNA sample in a total volume of 10 µl of annealing buffer,
incubated for 2 min at 85 °C and for 10 min at 65 °C, and slowly
cooled to 25 °C. The primer was extended by the addition of 5 µl
of RT(+) buffer and 12.5 units of avian myeloblastosis virus RT enzyme
(Roche Molecular Biochemicals) in a 15-min incubation at 42 °C. The
samples were mixed with formamide-loading buffer and analyzed on a
denaturing 6% polyacrylamide-urea-sequencing gel. Sequence reactions
initiated by the primers AD-SD or Lys-21 were included on the
sequencing gels to determine the exact positions of modification or cleavage.
 |
RESULTS |
Design of U5 Leader Stem Mutants--
To study the role of the U5
leader stem in reverse transcription, we constructed two deletion
mutants (Fig. 1B). Mutant d1 contains a large deletion on left side of the U5 leader stem (positions +112 to +148), and mutant d2 contains a deletion on the right side of
the stem (positions +216 to +242). The double mutant d1/2 combines both
deletions. A second set of more subtle mutants was designed to change
the individual stem segments of the U5 leader structure as illustrated
in Fig. 1C. The upper stem segment 1 was mutated by a 7-nt
substitution either on the left side in mutant 1L or on the right
side in mutant 1R. Mutations 1L and 1R are complementary, and base
pairing will be restored in the double mutant 1LR, at least according
to the RNA secondary structure model in Fig. 1. Similar type of
mutations were introduced in stem segment 2 (2L, 2R, and 2LR) and
segment 3 (3L, 3R, and 3LR). In addition, the left arm (positions +134
to +148) and the right arm (positions +224 to +233) of the U5 leader
structure were deleted in mutants dL and dR, respectively. Both
deletions were combined in the double mutant dLR.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic of the HIV-1 5'-untranslated
leader RNA. A, RNA secondary structure model of the
HIV-1 leader region. See Ref. 14 for further details on the individual
hairpin motifs. The tRNA primer
binds to the PBS (marked in green) that is part of an
extended RNA structure,. This structure consists of a small U5-PBS
hairpin that occludes part of the PBS and a large stem formed by
upstream U5 and downstream leader sequences. This U5 leader stem
(shaded) contains three distinct stem segments, the upper
segment 1, the middle segment 2, and the lower segment 3. The position
of several primers used in the reverse transcription assays is
indicated. B, shown are the deletions d1 and d2
(marked in blue) in the U5 leader stem. The double mutant
d1/2 contains both deletions. C, a second set of more subtle
U5 leader stem mutants was constructed. Mutant 1L has a 7-nt
substitution on the left side of stem 1, and mutant 1R has a 7-nt
substitution on the right side (marked in red).
Mutations 1L and 1R are complementary, and base pairing is restored in
the double mutant. Mutations were also introduced in stem 2 (2L, 2R,
and 2LR, marked in orange) and stem 3 (3L, 3R, and 3LR,
marked in yellow). In addition, we deleted the left and
right arms of the U5 leader stem in mutant dL and dR, respectively
(shown in blue). The deletions were combined in the double
mutant dLR.
|
|
Replication Capacity of U5 Leader Stem Mutants--
To study the
replication potential of viruses with U5 leader stem mutations, we
transfected wild-type and mutant proviral genomes into the SupT1 T cell
line. These cells express the CD4-CXCR4 receptors and are fully
susceptible for replication of the HIV-1 LAI strain. Virus replication
was followed by measuring the accumulation of CA-p24 in the culture
medium at several days post-transfection. Transfection with 1 µg of
the proviral constructs d1, d2, and d1/2 demonstrated that these
deletions completely impair virus replication (Fig.
2A), indicating that the U5
leader stem or sequence elements encoded by this region are important
for viral replication. To study the contribution of distinct sequence
or structure elements in more detail, we tested the second set of more
subtle mutants. Mutation of stem 1 had a minor effect on virus
replication (Fig. 2B). However, both mutations 2L and 2R in
the middle segment severely impaired virus replication, and the double
mutant did not restore replication (Fig. 2C). Mutation 3L in
the lower stem segment also reduced viral replication significantly,
whereas mutation 3R showed only a minor effect on viral replication
(Fig. 2D). The combination of both mutations in mutant 3LR
further reduced the replication capacity. Deletion dL did not
significantly affect virus replication, deletion dR showed a modest
defect, and combination of the mutations in mutant dLR further reduced
replication (Fig. 2E). These combined results indicate that
sequences within stem 2 of the U5 leader structure are most important
for virus replication.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
Replication of wild-type HIV-1 LAI
(wt) and U5 leader stem mutants. SupT1 cells were
transfected with 1 µg of the proviral constructs. CA-p24 production
was measured in the culture medium at several days post-transfection.
The replication capacity of the mutants d1 and d2 with large deletions
in the U5 leader stem and the double mutant d1/2 is shown in
A. Also shown is the replication capacity of viruses with
mutations in stem 1 (B), stem 2 (C), and stem 3 (D). The replication of the arm-deletion mutants dL, dR, and
dLR is shown in E.
|
|
Reverse Transcription on the Mutant HIV-1 Templates--
We next
performed in vitro reverse transcription reactions with the
wild-type and mutant HIV-1 RNA templates. RNA templates encompassing
the complete untranslated leader region (positions +1 to +368) were
used with the natural tRNA primer or
DNA primers to initiate reverse transcription. The position of the
different primers is shown in Fig. 1A. The primers were heat-annealed onto the different RNA templates, and reverse
transcription was initiated by the addition of dNTPs and HIV-1 RT
enzyme. Full-length reverse transcription products were quantitated and
corrected for the amount of input RNA template, as determined with the
DNA primer poly(A) (Fig. 3A,
lanes 1-4). Representative experiments are shown in Fig. 3.
The results of three independent assays were quantitated and are
summarized in Fig. 4.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 3.
Reverse transcription assays on wild-type and
mutant HIV-1 RNA templates. A, the amount of input
viral RNA was quantitated by DNA-primer extension with the poly(A)
primer that produces a 104-nt product (lanes 1-4). The
PBS-primer Lys-21 (lanes 5-8), and
tRNA (lanes 9-12) were
heat-annealed onto the HIV-1 RNA templates and extended by the HIV-1 RT
enzyme in the presence of all dNTPs. Extension of Lys-21 results in a
202-nt cDNA product, and the tRNA primer produces a 257-nt
tRNA-cDNA product. These sizes refer to reactions with the
wild-type template and are shorter for the d1 and d1/2 templates due to
the d1 deletion in the U5 region. Several shorter cDNA products are
visible that result from RT pausing. We also performed 1-nt
incorporation assays with the tRNA
primer (lanes 13-16). The extension of the 76-nt tRNA by
dCTP produces a 77-nt radiolabeled product. To accurately determine the
length of the cDNA products, a sequencing reaction was analyzed in
parallel (lanes 17-20). Part of the gels in panel
A and B, including the wild type (WT) and
marker lanes, was published previously (34). B,
PBS occupancy test in which the PBS-bound
tRNA primer was visualized by
selective extension of the downstream AUG primer (lanes
9-12). When the extension of the AUG primer is blocked by the
PBS-bound tRNA, a 175-nt cDNA was produced. Free RNA templates will
produce a full-length cDNA product of 374 nt (lanes
5-8). Control reactions were performed with the poly(A) primer
(lanes 1-4). To accurately determine the position of the
stop product, a sequence reaction was analyzed in parallel (lanes
13-16).
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Relative reverse transcription activities of
wild-type and d1, d2, and d1/2 mutant templates. The results of
three independent experiments were quantitated, and the activity of the
wild-type template was arbitrarily set at 1. Shown is DNA-primed
reverse transcription with the Lys-21 primer (A),
tRNA-primed reverse transcription (B), and tRNA-primed 1-nt
incorporation (C). The tRNA occupancy of the PBS is shown in
D and was also set at 1 (100% occupancy) for the wild-type
template.
|
|
Extension of the DNA primer Lys-21 that is complementary to the PBS
resulted in a 202-nt full-length cDNA product on the wild-type template, with a predicted change in cDNA length for the d1 and d1/2 templates due to the deletion in the U5 region (Fig.
3A, lanes 5-8). The efficiency of DNA-primed
reverse transcription is equal on all templates (Fig. 4A).
In contrast, extension of the natural tRNA primer, which results in a
257-nt cDNA product on the wild-type template, was abolished on the
d1 and d1/2 templates (Fig. 3A, lanes 9-12 and
Fig. 4B). Surprisingly, reverse transcription on the d2
template was stimulated 6-fold over the wild-type level. These
differences in tRNA-primed reverse transcription efficiency on the
mutant templates could result from differences in tRNA annealing,
initiation, or elongation. To study initiation of tRNA-primed reverse
transcription, the reaction was performed in the presence of
[32P]dCTP but without the other dNTPs. This will result
in the extension of the 76-nt tRNA
primer with 1 nt on all templates (Fig. 3A, lanes
13-16). The results of this initiation assay are similar to the
results of tRNA-primed full-length cDNA synthesis. No initiation
was observed on the d1 and d1/2 templates, whereas a 6-fold stimulation
was measured on the d2 template (Fig. 4C). This indicates
that the inhibitory effect of deletion d1 and the stimulatory effect of
deletion d2 are apparent at the level of initiation.
The observed differences in initiation efficiency may be caused by
different amounts of tRNA primer annealed onto the PBS. This seems
unlikely because the PBS motif itself is not altered in the mutant
HIV-1 templates, and the primer was heat-annealed in these studies. To
nevertheless rule out this possibility, we determined the tRNA
occupancy of the PBS on the wild-type and mutant templates. The tRNA
primer was annealed onto the template, and this complex was
subsequently used for extension of the DNA primer AUG that is
positioned downstream of the PBS (Fig. 1A). We used the
avian myeloblastosis virus RT enzyme to selectively extend the DNA
primer because this enzyme is unable to extend the tRNA primer (6, 34).
When the PBS was occupied by the tRNA primer, AUG-mediated reverse
transcription was blocked by the tRNA, yielding a cDNA product of
~175 nts. Free RNA templates will produce a full-length cDNA
product of 374 nts on the wild-type template. All templates exclusively
yield the stop product, indicating that the templates are fully
occupied by the tRNA primer (Fig.
3B, lanes 9-12). Control reactions were
performed with the upstream poly(A) primer and the AUG primer in the
absence of tRNA (Fig. 3B, lanes 1-4 and
5-8, respectively). The results of the PBS occupancy test
are summarized in Fig. 4D.
These combined results indicate a complex interplay of positive and
negative regulation of HIV-1 reverse transcription. The left side of
the U5 leader stem seems to encode a sequence motif that is involved in
initiation of reverse transcription. Deletion of the right side of the
stem may expose this sequence motif, thereby activating reverse
transcription. These effects are observed exclusively with the natural
tRNA primer and not with a PBS-bound
DNA primer, suggesting that additional tRNA-vRNA contacts may be involved.
The second set of stem mutants was designed to accurately map the
sequence motifs that regulate HIV-1 reverse transcription. Reverse
transcription assays were performed with these mutant templates and the
tRNA or Lys-21 DNA primer. All
reverse transcription products were quantitated and corrected for the
amount of input RNA template as determined by poly(A) primer extension
(Fig. 5A, polyA
panel). The results of three independent experiments are
summarized in Fig. 6. We measured no
difference among the templates in reverse transcription reactions initiated by the DNA primer Lys-21, whereas profound differences in
cDNA synthesis were observed in tRNA-primed reactions. Most severe
effects were observed with mutations in stem segment 2. Mutants 2L and
2LR showed 10-fold reduced tRNA-primed reverse transcription compared
with the wild-type template (Fig. 5A, tRNA panel,
lanes 4 and 6), whereas mutation 2R enhanced
reverse transcription 2.5-fold (lane 5). Mutation 3R also
stimulated reverse transcription (lane 8), and there is a
modest 3-fold inhibitory effect on reverse transcription with the
deletion mutants dL, dR, and dLR (lanes 10-12).
Furthermore, the observed reverse transcription effects are specific
for tRNA-primed reactions.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 5.
Reverse transcription assays on wild-type and
mutant templates. A, reverse transcription assays
primed with the primers poly(A), Lys-21, and
tRNA (see Fig. 3A for
further details). B, PBS-occupancy test (see Fig.
3B for further details).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Relative reverse transcription activities of
wild-type and mutant templates. The average of three independent
experiments was calculated, and the activity of the wild-type template
was set at 1. Shown is DNA-primed reverse transcription (A),
tRNA-primed reverse transcription (B), tRNA-primed 1-nt
incorporation (C), tRNA occupancy of the PBS
(D).
|
|
These effects are apparent at the level of initiation as
determined in the single nucleotide incorporation assay (Fig.
5A, tRNA1nt panel). The PBS
occupancy test demonstrated that the tRNA primer is annealed onto each
template with equal efficiency (Fig. 5B, tRNA/AUG
panel). Thus, mutations in stem segment 2 affect reverse transcription in a similar way as the deletion mutants d1 and d2.
Mutation of the left side of the stem inhibits reverse
transcription, whereas mutation of the right side stimulates reverse
transcription. These combined results suggest that the 2L sequence
activates the PBS-bound tRNA molecule to initiate reverse
transcription. We will therefore refer to this motif as the PAS.
Mutation of the PAS in mutant 2L inhibits reverse transcription,
whereas mutation 2R may stimulate initiation by making the PAS more
accessible. Mutation 3R also stimulates reverse transcription, which
may indicate that the opening of stem segment 3 weakens the stability
of the adjacent stem segment 2.
Structure Probing of the U5 Leader Stem--
The results presented
above suggest an important biological role for the U5 leader stem, in
particular for stem segment 2. We therefore determined the secondary
structure of the U5 leader stem by treating wild-type and mutant HIV-1
templates with structure-specific probes (Fig.
7). Nucleotides sensitive to the
chemicals DEPC or DMS and the RNases S1, T1, or One are assumed not to
be involved in base pairing or base-stacking interactions. The sites of
modification or cleavage were determined by primer extension analysis.
Control experiments were performed in parallel to detect pauses of
reverse transcription due to, for instance, stable RNA structure. The results of the probing experiments on the wild-type template are summarized in Fig. 8.

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 7.
RNA structure probing of the U5 leader stem
under native conditions. The wild-type RNA template was treated
with a limiting amount of the single strand-specific reagents.
Panel A, RNase T1 (G-specific), DEPC (A-specific), DMS
(A/C-specific). Panel B, RNase S1 and RNase One (both not
sequence-specific). Panel C, wild-type and mutant templates
(indicated on top of the panel) were treated with DEPC. Mock
incubations were performed in parallel ( ). Reactive sites were
detected using primer extension analysis with the downstream primer
AD-SD. The products were analyzed on a 6% polyacrylamide gel.
Positions of reactive sites are indicated, and the results are
summarized in Fig. 8.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
Modified RNA secondary structure model for
the U5-PBS-leader region of HIV-1. Based on structure probing
results, this region is folded into the U5 leader stem, the U5-top
hairpin, and the single-stranded PBS region. The reactive sites for the
individual structure-specific probes are indicated. The proposed base
pairing interaction between the HIV-1 PAS element and anti-PAS in the
T C arm of the tRNA primer is
marked in orange. The PBS-anti-PBS interaction is marked in
green.
|
|
Probing of the wild-type template with RNase T1 resulted in cleavage of
G residues at positions 202, 206, and 208 (Fig. 7A, lanes 1 and 2) that are single-stranded in the
structure model of Fig. 1. However, the G residues that are proposed to
be base-paired in stem 1 (G212-G214) are also
sensitive to RNase T1, indicating that this part of the structure model
is not correct. Probing of the wild-type template with the chemicals
DEPC (Fig. 7A, lanes 4 and 5) and DMS
(Fig. 7A, lanes 6 and 7) demonstrated
that several A residues in the single-stranded PBS region are exposed.
In addition, the A residues that are base-paired in stem 1 in Fig. 1
(A209-A211) were highly sensitive to both chemicals. Treatment with
RNase S1 and RNase One (Fig. 7B) resulted in several
cleavages in the single-stranded PBS region and the right arm of the U5
leader stem. RNase S1 also cleaves the U residues at position 153-156
that are proposed to be base-paired in stem 1 (Fig. 7B,
lanes 1 and 2, and results not shown). These
results indicate that the sequences proposed to be involved in base
pairing in stem 1 (Fig. 1) are present in a single-stranded region,
whereas the sequences in segment 2 and 3 are base-paired.
Additional evidence for the presence of stem 2 was obtained by probing
of this segment in the mutant templates. The right side of stem 2 is
not sensitive to DEPC treatment in the wild-type template (Fig.
7C, lanes 1 and 2), whereas mutation
2L on the left side exposed the sequence on the right side of stem 2. The nucleotides A225, A222, and
A220 become accessible to DEPC, indicating that they are
released from base pairing in mutant 2L (Fig. 7C,
lanes 9 and 10). In addition, cleavage at several
G residues in this G/A-rich stretch was observed. In the double mutant
2LR, these nucleotides are no longer accessible to DEPC (Fig.
7C, lanes 13 and 14),
indicating that base pairing in stem 2 is restored. In all other
mutants, stem 2 is not accessible to DEPC.
These combined results are consistent with a partially modified RNA
secondary structure model for the U5 leader stem that is shown in Fig.
8. The U5 leader stem segments 2 and 3 are maintained in this model,
but it shows the extended U5-top hairpin instead of stem 1 and the
U5-PBS hairpin. The residues U153-U156 that
are accessible to RNase S1 are positioned in the loop of the U5-top
hairpin, and the A-rich loop (positions 168-171) of the U5-PBS hairpin
is present as an internal loop. The right side of stem 1 is present in
the single-stranded PBS region that is highly sensitive to DEPC, DMS,
RNase T1, and RNase S1. The bulged-out A residues at positions 124, 132, and 133 are sensitive to DEPC and/or DMS. Positions 228-230 that
are highly accessible to RNase S1 and RNase One are present in loop of
the right arm of the U5 leader stem.
 |
DISCUSSION |
Reverse transcription of the HIV-1 RNA genome appears to be
strictly regulated at the level of initiation. Mutational analysis demonstrated that the sequence on the left side of segment 2 of the U5
leader stem is critical for initiation of reverse transcription but is
exclusively necessary in reactions primed by
tRNA . Mutation of this motif in
mutant 2L results in a 10-fold decrease in tRNA-primed reverse
transcription. This sequence motif is not required for annealing of the
tRNA primer onto the PBS but stimulates the incorporation of the first
dNTP. We will therefore refer to this sequence as the PAS. We propose
that the PAS sequence base pairs with the T C arm of the tRNA
molecule (Fig. 8), similar to the additional interaction proposed for
the RSV genome and the corresponding tRNATrp primer. The
PAS-anti-PAS interaction does not require additional melting of the
tRNA because PBS-anti-PBS annealing will open both the acceptor en
T C stems. However, the PAS sequence in the HIV-1 genome is occluded
by base pairing in the U5 leader stem, as was demonstrated by
biochemical probing experiments and, thus, needs to be unwound for the
interaction with the tRNA primer. The presence of the PAS enhancer
motif that is initially repressed by base pairing provides a unique
mechanism for positive and negative regulation of HIV-1 reverse
transcription. Consistent with this idea, reverse transcription is
stimulated up to 6-fold by opening of the U5 leader stem in mutants d2
and 2R. Virus replication studies demonstrated that mutant 2L and, in
particular, the deletion mutant d1 are replication impaired.
Furthermore, faster-replicating revertant viruses of mutant 2L were
obtained in five independent long term cultures. All these revertants
were found to contain a G-to-A mutation at position 127 within the 2L
motif (results not shown). This mutation partially repairs the
PAS-anti-PAS interaction, suggesting that this interaction is important
for virus replication.
A similar interaction between a U5 motif in the genome of RSV and the
T C arm of the tRNATrp primer has been demonstrated to
stimulate initiation of reverse transcription (22), and a similar
vRNA-tRNA interaction was also proposed for HIV-2 (20). These combined
results suggest that retroviral reverse transcription is activated by a
common mechanism. However, there are also some differences between the HIV-1 and RSV mechanisms. For instance, although the RSV genome folds a
similar U5 leader stem, the PAS enhancer is not base-paired in RSV but
rather positioned in a single-stranded region opposite the PBS (21).
This suggests that initiation of RSV reverse transcription cannot be
down-regulated by masking of the PAS motif, arguing that regulation of
reverse transcription may be more complex in HIV-1. Mutations in RSV
that disrupt the structure of either the U5 leader stem or the U5 IR
hairpin, the latter the equivalent of the HIV-1 U5-top hairpin, were
reported to impair the initiation of reverse transcription, whereas
mutations that alter the sequence but that retain the structure had no
effect (8, 9, 24). Similar mutations that disrupt the structure of the
U5 leader stem in HIV-1 were found to stimulate reverse transcription,
probably by exposure of the PAS enhancer. In a previous study, we
demonstrated that stabilization of the U5 leader stem inhibited
initiation of reverse transcription and virus replication (34).
Analysis of a faster-replicating revertant virus demonstrated that
opening of stem segment 2 by additional mutations on the right side
restored reverse transcription. These combined results suggest that the efficiency of HIV-1 reverse transcription is determined by the accessibility of the PAS enhancer and that the structure of the U5 leader stem can negatively modulate reverse transcription.
Several alternative interactions between the
tRNA molecule and the HIV-1 RNA
genome have been proposed on the basis of extensive biochemical probing
experiments and modeling studies (12, 30, 35). The A-rich loop of the
U5-PBS hairpin was proposed to interact with the U-rich anti-codon loop of tRNA (12, 13, 25-30). In
addition, the left arm of the U5 leader stem (positions +141 to +144)
was suggested to interact with the 3' portion of the anticodon stem of
the tRNA molecule. Some of these interactions were also tested by
mutational analysis in in vitro reverse transcription assays (36). Although our mutant set was not designed to test these interactions, the +141 to +144 motif is deleted in mutant dL, which
shows a 3-fold defect in reverse transcription. The interaction between
the PAS and the T C arm of tRNA seems more important because deletion of the PAS motif results in a
10-fold inhibition. However, other vRNA-tRNA contacts, in addition to
the PBS-anti-PBS and PAS-anti-PAS interactions, may contribute to the
efficient initiation of reverse transcription. The critical role of the
PAS element in tRNA usage is further supported by recent experiments in
our laboratory. By simultaneous alteration of the PAS and PBS motifs to
accommodate another tRNA molecule, we could modulate the identity of
the priming tRNA species.2
Furthermore, the PAS motif is absolutely conserved among all HIV-1 isolates.
The RNA secondary structure probing experiments performed in this study
suggest an alternative folding of the upper part of the U5 leader stem
(segment 1) and the U5-PBS hairpin to form the U5-top hairpin (Fig. 8).
Nucleotides A168-A171 that form the A-rich
loop of the U5-PBS hairpin are present in an internal loop of the
U5-top hairpin. This RNA secondary structure model was proposed
previously (16, 17) and is very similar to the RNA structure model for
HIV-2 (20). In this modified RNA structure model, the PAS and PBS
sequences are juxtaposed, which may facilitate tRNA annealing to both
motifs to trigger initiation of reverse transcription. It remains
possible that both RNA conformations play a role in specific stages of
the viral life cycle. For instance, there is some phylogenetic support
for the U5-PBS hairpin (20, 23), and alternative RNA conformations have
been reported to exist for other domains of the HIV-1 leader RNA (18,
19). In a previous study, we designed mutations in the HIV-1 leader RNA
to specifically stabilize or destabilize the U5-PBS hairpin (11).
Destabilization of the U5-PBS hairpin affects virus replication and the
correct placement of the tRNA primer onto the PBS. However, these
mutations also destabilize the U5-top hairpin conformation.
Stabilization of the U5-PBS hairpin affects virus replication and
inhibits tRNA annealing onto the PBS. Fast replicating revertant
viruses were selected with additional mutations that reduce the
stability of the modified U5-PBS hairpin and, thus, may restore folding
of the U5-top hairpin. Another complicating factor is that the region
upstream of the PBS encodes a critical sequence element that is
recognized as part of the proviral DNA by the viral integrase protein
(37, 38). Further studies are required to provide more insight into the
function of the U5-PBS and/or U5-top hairpin conformations.
A surprising result of this study is that the wild-type HIV-1 RNA
template appears sub-optimal for in vitro reverse
transcription, as the initiation step is actively suppressed by RNA
secondary structure. We propose that this mechanism may preclude
premature reverse transcription in the virus-producing cell such that
the viral RNA genome is copied only after it is appropriately dimerized and packaged into virions. This mechanism would rigidly limit reverse
transcription to the correct template and, hence, protect the host cell
from potentially deleterious unrestricted reverse transcription (39).
Replication studies with the wild-type and mutant viruses do suggest
that this restriction of reverse transcription is also beneficial for
virus replication. The mutations d2 and 2R stimulate reverse
transcription in vitro but impair virus replication. We are
currently testing whether these mutations do also activate reverse
transcription in vivo in virus-producing cells and virion particles. A complicating factor is that these mutations may also affect other steps in viral replication, thereby causing a replication defect. The U5 leader region has been reported to encode signals important for viral replication (40, 41). For instance, this region was
reported to encode DNA binding sites for transcription factors as part
of the proviral LTR promoter (42-45). We therefore measured the effect
of the mutations on viral gene expression by measuring virus production
in transiently transfected cells. Most mutations did not affect
transcription, translation, and virion assembly, except for mutations
d2 and 2R, which reduced virus production 4- and 2-fold, respectively
(results not shown). This production defect will also contribute to the
observed replication defect of these mutants, which makes it difficult
to extrapolate the defect that may be due to premature reverse transcription.
Occlusion of the PAS motif by base pairing may provide a mechanism to
restrict early reverse transcription. Although binding of
tRNA to the PBS can occur relatively early, e.g. in virus-producing cells, primer activation will
require a structural rearrangement of the vRNA-tRNA complex to
establish the PAS-anti-PAS interaction. It is possible that the viral
nucleocapsid (NC) protein, which acts as an RNA chaperone (reviewed in
Ref. 46), can mediate this conformational change. Because NC is only released from the Gag precursor protein during maturation of virion particles, this mechanism will ensure the precise timing for activation of reverse transcription. We recently described a conformational switch
in the HIV-1 leader RNA, which is mediated by NC (19). An extended form
of the U5 leader hairpin was shown to mask the downstream RNA
dimerization initiation signal, which can subsequently be exposed by
NC. This raises the interesting possibility that a single RNA structure
in the HIV-1 genome is used to mask the "late" RNA signals that
control dimerization and primer activation. This mechanism will also
ensure that both signals are activated simultaneously by the NC protein
during virion assembly.
 |
ACKNOWLEDGEMENTS |
We thank Wim van Est for photography work,
Hendrik Huthoff for critical reading of the manuscript, and Dr. D. Stammers for the gift of purified HIV-1 RT enzyme (obtained through the
Medical Research Council AIDS Reagent Project).
 |
FOOTNOTES |
*
This work was supported in part by the Netherlands
Foundation for Chemical Research with financial aid from the
Netherlands Organization for Scientific Research (NWO-CW).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Human
Retrovirology, Academic Medical Center, University of Amsterdam, P. O.
Box 22700, 1100 DE Amsterdam, The Netherlands. Tel.: 31-20-5664822; Fax: 31-20-6916531, E-mail: B.Berkhout@amc.uva.nl.
Published, JBC Papers in Press, May 30, 2001, DOI 10.1074/jbc.M102441200
2
N. Beerens and B. Berkhout, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
RT, reverse
transcriptase;
PBS, primer binding site;
HIV-1, human immunodeficiency
virus type 1;
RSV, Rous sarcoma virus;
vRNA, viral RNA;
PAS, primer
activation signal;
LTR, long terminal repeat;
PCR, polymerase chain
reaction;
DEPC, diethyl pyrocarbonate;
DMS, dimethyl sulfate;
NC, nucleocapsid;
nt, nucleotide(s).
 |
REFERENCES |
| 1.
|
Telesnitsky, A.,
and Goff, S. P.
(1997)
Retroviruses
, pp. 121-160, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 2.
|
Marquet, R.,
Isel, C.,
Ehresmann, C.,
and Ehresmann, B.
(1995)
Biochimie (Paris)
77,
113-124
|
| 3.
|
Trono, D.
(1992)
J. Virol.
66,
4893-4900
|
| 4.
|
Lori, F.,
Veronese, F. D. M.,
De Vico, A. L.,
Lusso, P.,
Reitz, M. S., Jr.,
and Gallo, R. C.
(1992)
J. Virol.
66,
5067-5074
|
| 5.
|
Arts, E. J.,
Mak, J.,
Kleiman, L.,
and Wainberg, M. A.
(1994)
J. Gen. Virol.
75,
1605-1613
|
| 6.
|
Oude Essink, B. B.,
Das, A. T.,
and Berkhout, B.
(1996)
J. Mol. Biol.
264,
243-254
|
| 7.
|
Huang, Y.,
Wang, J.,
Shalom, A.,
Li, Z.,
Khorchid, A.,
Wainberg, M. A.,
and Kleiman, L.
(1997)
J. Virol.
71,
726-728
|
| 8.
|
Cobrinik, D.,
Soskey, L.,
and Leis, J.
(1988)
J. Virol.
62,
3622-3630
|
| 9.
|
Cobrinik, D.,
Aiyar, A.,
Ge, Z.,
Katzman, M.,
Huang, H.,
and Leis, J.
(1991)
J. Virol.
65,
3864-3872
|
| 10.
|
Cordell, B.,
Swanstrom, R.,
Goodman, H. M.,
and Bishop, J. M.
(1979)
J. Biol. Chem.
254,
1866-1874
|
| 11.
|
Beerens, N.,
Klaver, B.,
and Berkhout, B.
(2000)
J. Virol.
74,
2227-2238
|
| 12.
|
Isel, C.,
Ehresmann, C.,
Keith, G.,
Ehresmann, B.,
and Marquet, R.
(1995)
J. Mol. Biol.
247,
236-250
|
| 13.
|
Liang, C.,
Li, X.,
Rong, L.,
Inouye, P.,
Quan, Y.,
Kleiman, L.,
and Wainberg, M. A.
(1997)
J. Virol.
71,
5750-5757
|
| 14.
|
Berkhout, B.
(1996)
Progr. Nucleic Acid. Res. Mol. Biol.
54,
1-34
|
| 15.
|
Baudin, F.,
Marquet, R.,
Isel, C.,
Darlix, J. L.,
Ehresmann, B.,
and Ehresmann, C.
(1993)
J. Mol. Biol.
229,
382-397
|
| 16.
|
Rizvi, T. A.,
and Panganiban, A. T.
(1993)
J. Virol.
67,
2681-2688
|
| 17.
|
Damgaard, C. K.,
Dyhr-Mikkelsen, H.,
and Kjems, J.
(1998)
Nucleic Acids Res.
26,
3667-3676
|
| 18.
|
Berkhout, B.,
and vanWamel, J. L. B.
(2000)
RNA (N. Y.)
6,
282-295
|
| 19.
|
Huthoff, H. T.,
and Berkhout, B.
(2001)
RNA (N. Y.)
7,
143-157
|
| 20.
|
Berkhout, B.,
and Schoneveld, I.
(1993)
Nucleic Acids Res.
21,
1171-1178
|
| 21.
|
Morris, S.,
and Leis, J.
(1999)
J. Virol.
73,
6307-6318
|
| 22.
|
Aiyar, A.,
Cobrinik, D.,
Ge, Z.,
Kung, H. J.,
and Leis, J.
(1992)
J. Virol.
66,
2464-2472
|
| 23.
|
Berkhout, B.
(1997)
Nucleic Acids Res.
25,
4013-4017
|
| 24.
|
Miller, J. T.,
Ge, Z.,
Morris, S.,
Das, K.,
and Leis, J.
(1997)
J. Virol.
71,
7648-7656
|
| 25.
|
Arts, E. J.,
Ghosh, M.,
Jacques, P. S.,
Ehresmann, B.,
and Le Grice, S. F. J.
(1996)
J. Biol. Chem.
271,
9054-9061
|
| 26.
|
Arts, E. J.,
Stetor, S. R.,
Li, Y.,
Rausch, J. W.,
Howard, K. J.,
Ehresmann, B.,
North, T. W.,
Wohrl, B. M.,
Goody, R. S.,
Wainberg, M. A.,
and Le Grice, S. F. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10063-10068
|
| 27.
|
Wakefield, J. K.,
Kang, S.-M.,
and Morrow, C. D.
(1996)
J. Virol.
70,
966-975
|
| 28.
|
Wakefield, J. K.,
and Morrow, C. D.
(1996)
Virology
220,
290-298
|
| 29.
|
Huang, Y.,
Khorchid, A.,
Gabor, J.,
Wang, J.,
Li, X.,
Darlix, J.-L.,
Wainberg, M. A.,
and Kleiman, L.
(1998)
J. Virol.
72,
3907-3915
|
| 30.
|
Isel, C.,
Keith, G.,
Ehresmann, B.,
Ehresmann, C.,
and Marquet, R.
(1998)
Nucleic Acids Res.
26,
1198-1204
|
| 31.
|
Das, A. T.,
Klaver, B.,
Klasens, B. I. F.,
van Wamel, J. L. B.,
and Berkhout, B.
(1997)
J. Virol.
71,
2346-2356
|
| 32.
|
Klaver, B.,
and Berkhout, B.
(1994)
J. Virol.
68,
3830-3840
|
| 33.
|
Back, N. K. T.,
Nijhuis, M.,
Keulen, W.,
Boucher, C. A. B.,
Oude Essink, B. B.,
van Kuilenburg, A. B. P.,
Van Gennip, A. H.,
and Berkhout, B.
(1996)
EMBO J.
15,
4040-4049
|
| 34.
|
Beerens, N.,
Groot, F.,
and Berkhout, B.
(2000)
Nucleic Acids Res.
28,
4130-4137
|
| 35.
|
Isel, C.,
Westhof, E.,
Massire, C.,
Le Grice, S. F. J.,
Ehresmann, B.,
Ehresmann, C.,
and Marquet, R.
(1999)
EMBO J.
18,
1038-1048
|
| 36.
|
Liang, C.,
Rong, L.,
Gotte, M.,
Li, X.,
Quan, Y.,
Kleiman, L.,
and Wainberg, M. A.
(1998)
J. Biol. Chem.
273,
21309-21315
|
| 37.
|
Esposito, D.,
and Craigie, R.
(1998)
EMBO J.
17,
5832-5843
|
| 38.
|
Masuda, T.,
Kuroda, M. J.,
and Harada, S.
(1998)
J. Virol.
72,
8396-8402
|
| 39.
|
Dhellin, O.,
Maestre, J.,
and Heidmann, T.
(1997)
EMBO J.
16,
6590-6602
|
| 40.
|
Vicenzi, E.,
Dimitrov, D. S.,
Engelman, A.,
Migone, T.-S.,
Purcell, D. F. J.,
Leonard, J.,
Englund, G.,
and Martin, M. A.
(1994)
J. Virol.
68,
7879-7890
|
| 41.
|
Liang, C.,
Rong, L.,
Russell, R. S.,
and Wainberg, M. A.
(2000)
J. Virol.
74,
6251-6261
|
| 42.
|
Van Lint, C.,
Amella, C. A.,
Emiliani, S.,
John, M.,
Jie, T.,
and Verdin, E.
(1997)
J. Virol.
71,
6113-6127
|
| 43.
|
Lenz, C.,
Scheid, A.,
and Schaal, H.
(1997)
J. Virol.
71,
2757-2764
|
| 44.
|
Liang, C.,
Li, X.,
Quan, Y.,
Laughrea, M.,
Kleiman, L.,
Hiscott, J.,
and Wainberg, M. A.
(1997)
J. Mol. Biol.
272,
167-177
|
| 45.
|
El Kharroubi, A.,
Piras, G.,
Zensen, R.,
and Martin, M. A.
(1998)
Mol. Cell. Biol.
18,
2535-2544
|
| 46.
|
Rein, A.,
Henderson, L. E.,
and Levin, J. G.
(1998)
Trends Biochem. Sci.
23,
297-301
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Bilbille, F. A. P. Vendeix, R. Guenther, A. Malkiewicz, X. Ariza, J. Vilarrasa, and P. F. Agris
The structure of the human tRNALys3 anticodon bound to the HIV genome is stabilized by modified nucleosides and adjacent mismatch base pairs
Nucleic Acids Res.,
June 1, 2009;
37(10):
3342 - 3353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Thomas, W. J. Bosche, T. L. Shatzer, D. G. Johnson, and R. J. Gorelick
Mutations in Human Immunodeficiency Virus Type 1 Nucleocapsid Protein Zinc Fingers Cause Premature Reverse Transcription
J. Virol.,
October 1, 2008;
82(19):
9318 - 9328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. M. Abbink and B. Berkhout
RNA Structure Modulates Splicing Efficiency at the Human Immunodeficiency Virus Type 1 Major Splice Donor
J. Virol.,
March 15, 2008;
82(6):
3090 - 3098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ooms, T. E. M. Abbink, C. Pham, and B. Berkhout
Circularization of the HIV-1 RNA genome
Nucleic Acids Res.,
August 7, 2007;
(2007)
gkm564v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-i. Sakuragi, S. Sakuragi, and T. Shioda
Minimal Region Sufficient for Genome Dimerization in the Human Immunodeficiency Virus Type 1 Virion and Its Potential Roles in the Early Stages of Viral Replication
J. Virol.,
August 1, 2007;
81(15):
7985 - 7992.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ooms, D. Cupac, T. E. M. Abbink, H. Huthoff, and B. Berkhout
The availability of the primer activation signal (PAS) affects the efficiency of HIV-1 reverse transcription initiation
Nucleic Acids Res.,
March 12, 2007;
35(5):
1649 - 1659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Konstantinova, P. de Haan, A. T. Das, and B. Berkhout
Hairpin-induced tRNA-mediated (HITME) recombination in HIV-1.
Nucleic Acids Res.,
January 1, 2006;
34(8):
2206 - 2218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Kasprzak, E. Bindewald, and B. A. Shapiro
Structural polymorphism of the HIV-1 leader region explored by computational methods
Nucleic Acids Res.,
December 20, 2005;
33(22):
7151 - 7163.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wei, S. Cen, M. Niu, F. Guo, and L. Kleiman
Defective Replication in Human Immunodeficiency Virus Type 1 When Non-Primers Are Used for Reverse Transcription
J. Virol.,
July 15, 2005;
79(14):
9081 - 9087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Buxton, G. Tachedjian, and J. Mak
Analysis of the Contribution of Reverse Transcriptase and Integrase Proteins to Retroviral RNA Dimer Conformation
J. Virol.,
May 15, 2005;
79(10):
6338 - 6348.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Yuste, A. V. Borderia, E. Domingo, and C. Lopez-Galindez
Few Mutations in the 5' Leader Region Mediate Fitness Recovery of Debilitated Human Immunodeficiency Type 1 Viruses
J. Virol.,
May 1, 2005;
79(9):
5421 - 5427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Roldan, O. U. Warren, R. S. Russell, C. Liang, and M. A. Wainberg
A HIV-1 Minimal Gag Protein Is Superior to Nucleocapsid at in Vitro Annealing and Exhibits Multimerization-induced Inhibition of Reverse Transcription
J. Biol. Chem.,
April 29, 2005;
280(17):
17488 - 17496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Das, M. Vink, and B. Berkhout
Alternative tRNA Priming of Human Immunodeficiency Virus Type 1 Reverse Transcription Explains Sequence Variation in the Primer-Binding Site That Has Been Attributed to APOBEC3G Activity
J. Virol.,
March 1, 2005;
79(5):
3179 - 3181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Paillart, M. Dettenhofer, X.-f. Yu, C. Ehresmann, B. Ehresmann, and R. Marquet
First Snapshots of the HIV-1 RNA Structure in Infected Cells and in Virions
J. Biol. Chem.,
November 12, 2004;
279(46):
48397 - 48403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. M. Abbink, N. Beerens, and B. Berkhout
Forced Selection of a Human Immunodeficiency Virus Type 1 Variant That Uses a Non-Self tRNA Primer for Reverse Transcription: Involvement of Viral RNA Sequences and the Reverse Transcriptase Enzyme
J. Virol.,
October 1, 2004;
78(19):
10706 - 10714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Miller, A. Khvorova, S. A. Scaringe, and S. F. J. Le Grice
Synthetic tRNALys,3 as the replication primer for the HIV-1HXB2 and HIV-1Mal genomes
Nucleic Acids Res.,
September 1, 2004;
32(15):
4687 - 4695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Goldschmidt, J.-C. Paillart, M. Rigourd, B. Ehresmann, A.-M. Aubertin, C. Ehresmann, and R. Marquet
Structural Variability of the Initiation Complex of HIV-1 Reverse Transcription
J. Biol. Chem.,
August 20, 2004;
279(34):
35923 - 35931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. A. Voronin and V. K. Pathak
Frequent Dual Initiation in Human Immunodeficiency Virus-Based Vectors Containing Two Primer-Binding Sites: a Quantitative In Vivo Assay for Function of Initiation Complexes
J. Virol.,
May 15, 2004;
78(10):
5402 - 5413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rigourd, V. Goldschmidt, F. Brule, C. D. Morrow, B. Ehresmann, C. Ehresmann, and R. Marquet
Structure-function relationships of the initiation complex of HIV-1 reverse transcription: the case of mutant viruses using tRNAHis as primer
Nucleic Acids Res.,
October 1, 2003;
31(19):
5764 - 5775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Beck and M. Nassal
Efficient Hsp90-independent in Vitro Activation by Hsc70 and Hsp40 of Duck Hepatitis B Virus Reverse Transcriptase, an Assumed Hsp90 Client Protein
J. Biol. Chem.,
September 19, 2003;
278(38):
36128 - 36138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Huthoff, K. Bugala, J. Barciszewski, and B. Berkhout
On the importance of the primer activation signal for initiation of tRNAlys3-primed reverse transcription of the HIV-1 RNA genome
Nucleic Acids Res.,
September 1, 2003;
31(17):
5186 - 5194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Iwatani, A. E. Rosen, J. Guo, K. Musier-Forsyth, and J. G. Levin
Efficient Initiation of HIV-1 Reverse Transcription in Vitro. REQUIREMENT FOR RNA SEQUENCES DOWNSTREAM OF THE PRIMER BINDING SITE ABROGATED BY NUCLEOCAPSID PROTEIN-DEPENDENT PRIMER-TEMPLATE INTERACTIONS
J. Biol. Chem.,
April 11, 2003;
278(16):
14185 - 14195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-I. Sakuragi, S. Ueda, A. Iwamoto, and T. Shioda
Possible Role of Dimerization in Human Immunodeficiency Virus Type 1 Genome RNA Packaging
J. Virol.,
April 1, 2003;
77(7):
4060 - 4069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. M. Abbink and B. Berkhout
A Novel Long Distance Base-pairing Interaction in Human Immunodeficiency Virus Type 1 RNA Occludes the Gag Start Codon
J. Biol. Chem.,
March 21, 2003;
278(13):
11601 - 11611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Goldschmidt, C. Ehresmann, B. Ehresmann, and R. Marquet
Does the HIV-1 primer activation signal interact with tRNA3Lys during the initiation of reverse transcription?
Nucleic Acids Res.,
February 1, 2003;
31(3):
850 - 859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Goldschmidt, M. Rigourd, C. Ehresmann, S. F. J. Le Grice, B. Ehresmann, and R. Marquet
Direct and Indirect Contributions of RNA Secondary Structure Elements to the Initiation of HIV-1 Reverse Transcription
J. Biol. Chem.,
November 1, 2002;
277(45):
43233 - 43242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Clever, D. Miranda Jr., and T. G. Parslow
RNA Structure and Packaging Signals in the 5' Leader Region of the Human Immunodeficiency Virus Type 1 Genome
J. Virol.,
October 25, 2002;
76(23):
12381 - 12387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. G. Dirac, H. Huthoff, J. Kjems, and B. Berkhout
Requirements for RNA heterodimerization of the human immunodeficiency virus type 1 (HIV-1) and HIV-2 genomes
J. Gen. Virol.,
October 1, 2002;
83(10):
2533 - 2542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Morris, M. Johnson, E. Stavnezer, and J. Leis
Replication of Avian Sarcoma Virus In Vivo Requires an Interaction between the Viral RNA and the T{psi}C Loop of the tRNATrp Primer
J. Virol.,
June 27, 2002;
76(15):
7571 - 7577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Berkhout, M. Ooms, N. Beerens, H. Huthoff, E. Southern, and K. Verhoef
In Vitro Evidence That the Untranslated Leader of the HIV-1 Genome Is an RNA Checkpoint That Regulates Multiple Functions through Conformational Changes
J. Biol. Chem.,
May 24, 2002;
277(22):
19967 - 19975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Beerens and B. Berkhout
The tRNA Primer Activation Signal in the Human Immunodeficiency Virus Type 1 Genome Is Important for Initiation and Processive Elongation of Reverse Transcription
J. Virol.,
March 1, 2002;
76(5):
2329 - 2339.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|